A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...

The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said. Both the anti-arrhythmia drug ...

PHILADELPHIA -- For atrial fibrillation (Afib) patients with obesity, a second set of defibrillation pads for dual direct current cardioversion safely improved the success of the procedure, a ...

Atrial fibrillation (AFib) is a kind of irregular heartbeat, or arrhythmia. A problem with the electrical signals that control your heart’s pumping action causes it to beat too fast in a pattern that ...

Sinus rhythm was restored in an effective, safe and rapid manner using drug-shock or shock-only strategies among patients in the ED with acute atrial fibrillation, according to results of the RAFF-2 ...

Researchers conducted a retrospective chart review of 78 patients with severe obesity (class III, BMI ≥ 35 to < 40 or class IV, BMI ≥ 40; mean BMI, 39.9; 51% men) who underwent direct current ...

ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...

I recently diagnosed atrial fibrillation in a 24-year-old man with new-onset chest pain, irregular palpitations, and heart rate >170 beats per minute. The patient has no history of drug or tobacco ...

Hubner and colleagues in the UK have recently described a simplified cardioversion service that has significantly reduced waiting times at their center. They have introduced intravenous midazolam ...

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has published a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology titled Novel Low-Voltage MultiPulse ...

MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has been awarded a $3 million National Institutes of Health (NIH) Phase IIb SBIR grant for the development of an implantable, low-energy therapy for the ...